Advancing ADC development through target expression insights
Kristien Borremans, PhD, KU Leuven, Louvain, Belgium, comments on how findings from assessing mRNA expression of antibody-drug conjugate (ADC) targets in normal and metastatic breast cancer tissues can guide Phase I clinical trial design. The data may help identify promising targets, predict on-target toxicities, and anticipate side effects for better prevention and management. Insights into unexpected target expression in normal tissues could optimize ADC development, enhancing patient safety and therapeutic efficacy. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
